Table 1 Patient demographics.
Patient | Age (Yrs) | Ethnicity | Diagnosis | Clinical Disease at Blood Sampling | Treatment |
|---|---|---|---|---|---|
1 | 50 | Black | Relapse ER+PR+Her2− | Yes | Hormone |
2 | 35 | Hispanic | Relapse ER-PR-Her2− | Yes | Chemotherapy |
3 | Black | Relapse ER-PR-Her2− | Yes | Chemotherapy | |
4 | 60 | Black | Stage II | No | Adjuvant: Doxorubicin, cyclophosphamide |
5 A | 40–49 | Caucasian | Relapse ER+PR+Her2− | Yes | Pre-Chemotherapy (Palbociclib) |
5B | ↓ | ↓ | ↓ | No | Post-Chemotherapy |
6 | 63 | Caucasian | Benign (needle biopsy) | No | None |
7 | 58 | Hispanic | ER-PR-Her2−Stage I | No | Lumpectomy; radiation; chemotherapy (Paclitaxel and Carboplatin) |
8 | 54 | Caucasian | ER-PR-Her2−Stage II | No | Surgery (mastectomy), Chemotherapy |
9 | 36 | Black | ER+PR+Her2+ | No | Post-surgery, radiation, Herceptin; Chemotherapy (AC → T); On Tamoxifen |
10 | 53 | Hispanic | Stage II ER+PR+Her2+ | No | Lumpectomy; 4 cycles Paclitaxel; One year Herceptin; 4 yrs Tamoxifen |
11 | 56 | Hispanic | Stage III ER+PR-Her2+ | No | Mastectomy; Radiation; Chemotherapy (Docetaxel, Paclitaxel, Herceptin) |
12 | 56 | Hispanic | Stage I ER+PR-Her2− | No | Mastectomy; Taxol, No radiation, On Tamoxifen |
13 | 66 | Black | Stage IV ER+PR+Her2+ | Yes | Taxotere; Herceptin, Hormone (Faslodex) Post-chemotherapy – bone pain |
14 | 64 | Hispanic | Stage I ER+PR+Her2+ | No | ECOG 5103 Trial (Bevacizumab), Herceptin, Hormone (Arimidex) |
15 | 59 | Black | ER+PR+Her2− Stage II | No | Lumpectomy, radiation, chemotherapy (AC → T); Hormone (Tamoxifen) |
16 | 50 | Caucasian | Stage III ER+PR+Her2+ | No | Post-treatment (Chemotherapy and surgery) |
17 | 48 | Hispanic | Stage III ER-PR-Her2− | No | Post-treatment (2015); follow-up |
18 | 45 | Black | Stage II (2006); Relapse (2015) ER-PR- Her2− | Chest wall (2015) | Mastectomy at initial diagnosis (2006); Radiation in 2015 |
19 | 48 | Hispanic | Stage IIA ER+PR+Her2+ | No | Mastectomy; Completed Chemotherapy (Adriamycin, Cytoxan, Paclitaxel); Hormone (Tamoxifen)_ |
20 | 85 | Black | Stage IV ER+PR+Her2− | Yes | Hormone (Arimidex) |
